Cargando…
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2
BACKGROUND: Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to emerge in 2020 and have been spreading globally during the coronavirus disease 2019 (COVID-19) pandemic. Despite the presence of different COVID-19 vaccines, the discovery of effective antiviral the...
Autores principales: | Ngwe Tun, Mya Myat, Sakura, Takaya, Sakurai, Yasuteru, Kurosaki, Yohei, Inaoka, Daniel Ken, Shioda, Norifumi, Yasuda, Jiro, Kita, Kiyoshi, Morita, Kouichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739347/ https://www.ncbi.nlm.nih.gov/pubmed/34991723 http://dx.doi.org/10.1186/s41182-021-00397-x |
Ejemplares similares
-
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2022) -
5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
por: Sakurai, Yasuteru, et al.
Publicado: (2021) -
The Antiviral Effect of the Chemical Compounds Targeting DED/EDh Motifs of the Viral Proteins on Lymphocytic Choriomeningitis Virus and SARS-CoV-2
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2021) -
Persistence of Neutralizing Antibody Against Dengue Virus 2 After 70 Years from Infection in Nagasaki
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2016) -
Ending tuberculosis by 2030: understanding the transmission
por: Pandey, Basu Dev, et al.
Publicado: (2023)